Advantage Clinical Trials | Bronx, NY

Research site

(Unclaimed)

Location

2386 Jerome Avenue, Bronx, New York, United States of America

Site insights

Top conditions

Top treatments

Upadacitinib

ABT-494

Ozanimod

Linaclotide

Tenapanor

Linagliptin

Gemcabene

IW-3718

SADBE

Vonoprazan

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 25 total trials

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 (U-ENDURE)

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting

Crohn's Disease

Drug: Placebo for Upadacitinib

Drug: Upadacitinib

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) (U-ACHIEVE)

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting

Ulcerative Colitis (UC)

Drug: Placebo

Drug: Upadacitinib (ABT-494)

Infant Formula and Toddler Drink Feeding Study

The purpose of this study is to evaluate the growth and development outcomes of infants fed a new infant formula and toddler drink through 24 months...

Active, not recruiting

Growth

Other: Human Milk

Other: Human Milk Toddler Drink

Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants) or 52 weeks (Irritable bowel syndrome with constipation...

Active, not recruiting

Functional Constipation

Irritable Bowel Syndrome With Constipation

Drug: Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)

Drug: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)

Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

VLA15-221 is a Phase 2 study, which will be conducted in two parts: Main Study Phase (Part A) and Booster Phase (Part B). The study will compare the...

Active, not recruiting

Lyme Borreliosis

Biological: VLA15

Biological: Placebo

Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

This study is to understand if the study vaccine (called VLA15) is safe in healthy children.We are looking for children who:* are healthy* are age 5...

Active, not recruiting

Lyme Disease

Other: Normal Saline

Biological: VLA15

Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C

Open-label long-term safety study of tenapanor in pediatric patients with IBS-C.

Invitation-only

Irritable Bowel Syndrome With Constipation (IBS-C)

Drug: Tenapanor

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediat...

Enrolling

Irritable Bowel Syndrome With Constipation (IBS-C)

Drug: Tenapanor 50 MG

Drug: Placebo